In India, plazomicin—a new antibiotic that can be injected once daily—has been introduced to address complicated urinary tract infections (cUTIs), particularly those stemming from multidrug-resistant bacteria. Due to increasing antimicrobial resistance (AMR), the incidence of cUTIs, which can result in severe conditions such as urosepsis, is on the rise. Men have a lower lifetime risk of UTIs (under 15%) compared to women (60%), but all UTIs in men are classified as complicated. The drug, initially developed by Achaogen and approved by the US FDA in 2018, is now marketed in India under the brand name Zemdri by Cipla. Plazomicin has shown effectiveness against Carbapenem-Resistant Enterobacteriaceae (CRE), offering hope amid failures of last-line antibiotics. This launch meets a vital healthcare requirement, with backing from the EPIC trial and data specific to India.